



Published in final edited form as:

Cancer Immunol Res. 2019 September ; 7(9): 1390–1395. doi:10.1158/2326-6066.CIR-18-0605.

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma

Ahmed Omar Kaseb¹, Luis Vence², Jorge Blando², Shalini S. Yadav², Naruhiko Ikoma³, Roberto Carmagnani Pestana⁴, Jean Nicolas Vauthey³, James P. Allison², Padmanee Sharma²

¹Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

²Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

³Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

⁴Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

In hepatocellular carcinoma (HCC), surgical resection is associated with high recurrence rate, and no effective adjuvant therapy currently exists. We initiated a pilot randomized trial of perioperative immunotherapy with nivolumab and ipilimumab for resectable HCC. Here, we provide an illustrative report of a case that achieved a complete response and report immunologic correlates of this complete pathologic response to perioperative immunotherapy. Clinical response was correlated with an increase in CD8⁺ T-cell infiltration, with an increase in two effector T-cell clusters. This study is ongoing, and the final results may contribute to a paradigm shift in the perioperative treatment of HCC, leading to the incorporation of immunotherapy in the curative setting.

Corresponding Authors: Ahmed Omar Kaseb, The University of Texas MD Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-2828; Fax: 713-563-0541; akaseb@mdanderson.org; and Padmanee Sharma, padsharma@mdanderson.org.

Authors' Contributions

Conception and design: A.O. Kaseb, N. Ikoma, R.C. Pestana, P. Sharma

Development of methodology: A.O. Kaseb, P. Sharma

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.O. Kaseb, L. Vence, N. Ikoma, P. Sharma

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.O. Kaseb, L. Vence, J. Blando, S.S. Yadav, J.N. Vauthey, J.P. Allison, P. Sharma

Writing, review, and/or revision of the manuscript: A.O. Kaseb, L. Vence, J. Blando, S.S. Yadav, N. Ikoma, R.C. Pestana, J.N. Vauthey, J.P. Allison, P. Sharma

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.O. Kaseb, R.C. Pestana

Study supervision: A.O. Kaseb, J.N. Vauthey, J.P. Allison

Disclosure of Potential Conflicts of Interest

P. Sharma has ownership interest (including stock, patents, etc.) in Jounce, Neon, Constellation, Forty Seven, and is a consultant/advisory board member for Jounce, Neon, Marker, Pieris, Imaginab, Constellation, Forty Seven, Optera, Hummingbird, BioAtla, Codiak, Polaris, and Oncolytics. No potential conflicts of interest were disclosed by the other authors.

Introduction

Hepatocellular carcinoma (HCC) is the most common liver cancer and is the second leading cause of cancer-related death worldwide (1). Surgical resection is potentially curative and has been considered the first-line treatment for operable HCC for the past decade (2). However, the recurrence rates after hepatic resection are high, reaching about 80% at 5 years (3). Preventing relapse after curative treatment remains a significant challenge, and no effective adjuvant therapy has been developed to date (3).

Antibodies blocking the immune-inhibitory pathways PD-1/PD-L1 and CTLA-4 have been used in cancer treatment, including HCC. The antibodies targeting PD-1, pembrolizumab and nivolumab, are currently approved for second-line treatment of HCC, achieving overall response rates of 15% to 20% (4, 5). Anti-CTLA-4, tremelimumab, has shown promising clinical activity in HCC, with response rates of 17% to 26% (6, 7).

The abovementioned results in metastatic HCC compare favorably to FDA-approved treatment options, and this has led to an ongoing, multicenter phase III trial evaluating nivolumab in the adjuvant setting (NCT03383458). A previous preclinical report by Liu and colleagues (8) suggests that efficacy of neoadjuvant immune checkpoint inhibition is increased compared with the same treatment in the adjuvant setting, and feasibility has been demonstrated in non-small cell lung cancer, melanoma, colorectal cancer, and urothelial bladder cancer (9–12). On the basis of these data, we initiated a randomized pilot trial of perioperative immunotherapy for resectable HCC at our institution (ClinicalTrials.gov, NCT03222076). Here, we provide an illustrative report of a case that achieved a complete response and report immunologic correlates of this complete pathologic response to perioperative immunotherapy.

Materials and Methods

Study details

We provide an illustrative case report of a patient that achieved a complete response and report the interim analysis of immune correlates of this complete pathologic response in a randomized phase II trial of perioperative immunotherapy for HCC (NCT03222076) that has accrued 9 patients, with 3 complete responders so far. The clinical trial has three treatment arms: perioperative nivolumab alone at a dose of 3 mg/kg every 2 weeks (arm A) in patients with resectable HCC, perioperative nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks; arm B) in patients with resectable HCC, and perioperative nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks; arm C) in patients with potentially resectable HCC. All arms included postoperative maintenance immunotherapy for up to 2 years with either single-agent nivolumab or the combination of nivolumab plus ipilimumab at the doses above. The primary endpoint was the safety and tolerability of perioperative therapy, and success was predefined as having at least 13 of 15 subjects receiving their assigned therapy in each arm without grade 3 or higher adverse events, necessitating a delay in the planned surgical resection. Written informed consent was obtained from all patients. The study was conducted in accordance with the Declaration of

Helsinki. All bio-specimens collected and used in the study were obtained under an institutional review board-approved protocol (PA13–0291).

Isolation and preparation of peripheral blood mononuclear cells and tissues

Whole blood was collected in cell preparation tubes (CPT) containing sodium heparin (BD Vacutainer) and centrifuged at $800 \times g$ for 25 minutes. The interface cells were harvested and washed twice with PBS and centrifuged at $500 \times g$ for 10 minutes. Peripheral blood mononuclear cells (PBMC) were then resuspended in AB serum with 10% (vol/vol) DMSO for storage in liquid nitrogen until the assays were performed. The time points collected and analyzed were pretreatment, post-Ipi/Nivo 1 (cycle 2), post-Ipi/Nivo 2 (cycle 3), posttreatment (hepatic resection), and posttreatment (cycle 6). Fresh tumor tissue was dissociated with GentleMACS system (Miltenyi Biotec) as per the manufacturer's instructions, collected, and subsequently prepared for mass cytometry analysis.

Mass cytometry

Mass cytometry (CyTOF) analyses were performed on liver lesions before treatment (pretreatment) and at the time of hepatic resection (posttreatment) to characterize the phenotype and subpopulations of tumor-infiltrating lymphocytes (TIL), and adjacent nontumoral liver tissue, as well as PBMCs. Single-cell suspensions were stained with 36 antibodies [CD45, CD326, TIGIT, CD68, CD73, CD4, CD8a, ICOS (CD278), OX40 (CD134), LAG-3 (CD223), PD-L1 (CD274), CD3, Galectin-9, TIM-3, HVEM (CD270), CD27, CD86, PD-1, VISTA, CD28, CD70, FoxP3, BTLA (CD272), 41BBL (CD137L), KI67, ICOSL (CD275), CD80, B7-H4, B7-H3, CTLA-4 (CD152), GITR (CD357), PD-L2 (CD273), OX40L, CD137 (4–1BB), CD56, HLA-DR, Ir DNA-Intercalator, and cisplatin]. Antibodies were either purchased preconjugated from Fluidigm or purchased purified and conjugated in-house using MaxPar X8 Polymer kits (Fluidigm) according to the manufacturer's instructions. Briefly, samples were stained fresh with cell surface antibodies in PBS containing 5% goat serum and 30% BSA for 30 minutes at 4°C. After viability staining with 5 $\mu\text{mol/L}$ cisplatin (Fluidigm) in PBS containing 30% BSA, samples were washed in PBS containing 30% BSA, fixed, and permeabilized according to manufacturers' instructions using the FoxP3 staining buffer set (eBioscience) before being incubated with intracellular antibodies in permeabilization buffer for 30 minutes at 4°C. Samples were washed and incubated in Ir intercalator (Fluidigm) and stored at 4°C until acquisition, generally within 12 hours. Right before acquisition samples were washed and resuspended in water containing EQ 4 element beads (Fluidigm). Samples were acquired on a Helios mass cytometer (Fluidigm).

Mass cytometry analysis

Files (fcs) were normalized using a bead-based normalization software for mass cytometry data (R package premissa, Parker Institute for Cancer Immunotherapy; ref. 13). Samples were then manually gated in FlowJo by event length, by live/dead discrimination, and for populations of interest using lineage markers (CD45) for separate analyses. Data were then exported into MATLAB as fcs files for downstream analysis and arcsinh transformed using a coefficient of 5 [$x_{\text{transformed}} = \text{arsinh}(x/5)$]. To visualize the high-dimensional data in two dimensions, the t-Distributed Stochastic Neighbor Embedding (t-SNE) dimension reduction

algorithm (14, 15) was applied to the cells, using all channels besides those used to manually gate the population of interest (e.g., CD45).

Mass cytometry clustering

Clustering analysis was performed using the MATLAB implementation of the PhenoGraph clustering algorithm (16). Clusters were identified using PhenoGraph on all the samples in the space formed by these principal components, with the parameter k for the number of nearest neighbors selected uniquely for each sample using the formula $k = \text{minimum}(0.002 * \text{number of cells}, 10)$. PhenoGraph was run with parameter $k = 30$, resulting in 30 clusters in the CD45⁺ analysis.

IHC staining and analysis

Hematoxylin and eosin (H&E) and IHC staining were performed on formalin-fixed, paraffin-embedded tissue sections. Tissues were fixed in 10% formalin, embedded in paraffin, and transversely sectioned. Four-micron-thick sections were used for the histopathologic study. Sections were stained with mouse or rabbit anti-human mAbs against CD3 (Dako, catalog no. A0452), CD8 (Thermo Fisher Scientific, MS-457-S), CD45RO (Novocastra, PA0146), Gr-B (Leica Microsystems, PA0291), PD-L1 (Cell Signaling Technology, 13684S), and FoxP3 (BioLegend, catalog no. 320102). All sections were counterstained with hematoxylin, and processed with peroxidase-conjugated avidin/biotin and 3'-3-diaminobenzidine (DAB) substrate (Leica Microsystems). Slides were scanned and digitalized using the scanscope system from Scanscope XT, Aperio/Leica Technologies. Quantitative analysis of IHC staining was conducted using the image analysis software Image-Scope-Aperio/Leica. Five random areas (1 mm² each) comprised of each pretreatment tumoral areas and posttreatment scar inflammatory tissues were selected using a customized algorithm for each marker to determine the number of positive cells at 20× magnification. The data are expressed as a density (total number of positive cells/mm² area). IHC staining was interpreted in conjunction with H&E-stained sections.

Case report

A 66-year-old woman with previously treated chronic hepatitis C virus (HCV) infection was diagnosed with localized, resectable, T2N0M0 (stage II), poorly to moderately differentiated HCC. Laboratory examination results demonstrated elevated alpha-fetoprotein (AFP; 681 ng/mL), and a CT scan showed two discrete liver lesions measuring 4.6 × 3.5 cm and 4.5 × 3.1 cm, both in liver segment 3 (Fig. 1A). Hepatitis C viral load was undetectable at time of diagnosis and remained undetectable throughout the treatment. The patient was randomly enrolled in arm B, of preoperative combination nivolumab plus ipilimumab. She was scheduled to receive 240 mg of intravenous nivolumab every 2 weeks for three doses, plus a single dose of 1 mg/kg i.v. ipilimumab on day 1 of the first cycle. However, the third dose of nivolumab was omitted because she experienced a transient grade 3 elevation of transaminases. Aspartate transaminase (AST) and alanine transaminase (ALT) returned to baseline after 8 weeks, and no additional measures were required.

At posttreatment, a preoperative CT scan demonstrated a treatment response: Both lesions were downsized to 3.5 cm in the maximum diameter and had a cyst-like appearance, without

arterial enhancement (Fig. 1B). AFP also decreased to 25 ng/mL. Four weeks after the second dose of nivolumab, the patient underwent resection of anatomic liver segment 3. The intraoperative liver appearance was normal, with minimal nodularity, and the postoperative course was uncomplicated. Pathologic examination revealed two hemorrhagic and necrotic liver lesions (3.0 and 3.7 cm in diameter), with no viable tumor cells. The patient resumed immunotherapy as per protocol (Fig. 2A) 4 weeks after surgery, with no additional grade 3 or higher toxicity.

Results

A total of 9 patients have been enrolled at the time of analysis, 5 in arm A and 4 in arm B. There were no delays in surgery related to immunotherapy treatment. Pathologic complete response was observed in 3 of 9 patients (33.3%). The case presented here is the first of these responders.

Immune correlates of complete response

An IHC analysis of the immune infiltrates in the tumor microenvironment showed an increase in T-cell infiltration in posttreatment tissue compared with pretreatment tissue (Fig. 2B and C). The infiltrates were predominantly composed of CD8⁺ T cells (Fig. 2B and C), and the expression T-cell activation markers CD45RO and granzyme B increased 2- and 3-fold, respectively (Fig. 2B). Foxp3 and PD-L1 expression on immune cells was increased after treatment (Fig. 2B).

CytoF analysis of the leukocytes from tumor, normal liver tissue, and PBMCs from pretreatment and posttreatment tissue yielded 30 clusters among the different leukocyte subpopulations (Fig. 3A). These clusters expressed different markers on the surface and intracellularly as shown in the heatmap in Fig 3B. The analysis of these clusters showed an increase in two effector CD8⁺ T-cell clusters in the posttreatment tumor tissue (Fig. 3C and D). These clusters consisted of CD3⁺CD8⁺CD45RO⁺Eomes⁺ cells (cluster 5) and CD3⁺CD8⁺CD45RO⁺Eomes⁺CD57⁺CD38^{low} cells (cluster 12; Fig. 3C and D, respectively). Regulatory T cells (Treg; CD3⁺CD4⁺CD45RO⁺Foxp3⁺ICOS⁺ cells, cluster 8) also showed an increase in posttreatment tumor tissue (Fig. 3E). The increase of these three clusters was in concordance with the increase in CD3⁺, CD8⁺, CD45RO⁺, and Foxp3⁺ T cells seen with IHC analysis (Fig. 2B). Subsequently, we evaluated the CD8⁺ T-cell/Treg ratio, which was calculated using the ratio of clusters 5 and 12 over cluster 8. The CD8⁺ T-cell/Treg ratio in the tumor microenvironment increased slightly after treatment with nivolumab and ipilimumab, from 4.7 to 6.2 (Fig. 3F). This ratio did not change in adjacent nontumoral liver samples (0.6–0.4; Fig. 3F).

Discussion

We provide a report of immunologic correlates of a complete pathologic response to preoperative immune checkpoint inhibitors in HCC. Surgical resection was performed safely, with no delays or complications. The clinical response was correlated with an increase in CD8⁺ T-cell infiltration, with an 11-fold increase in CD3⁺CD8⁺CD45RO⁺Eomes⁺ and a 6-fold increase in CD3⁺CD8⁺CD45RO⁺Eomes⁺CD57⁺CD38^{low} clusters. The

clusters that increased after treatment were effector CD8⁺ T cells expressing CD45RO and Eomes, both of which are very important for their antitumor function (17, 18). CD57 expressed by cells in cluster 12 defines a CD8⁺ T-cell subpopulation with high cytotoxic activity (19). Taken together, these data support the notion of highly cytotoxic effector CD8⁺ T cells entering the tumor after preoperative combined checkpoint inhibitor treatment, where they can then mount antitumor responses against HCC. T-cell infiltration was present in the tumor microenvironment prior to treatment, and this could have been due, at least in part, to prior chronic HCV infection (20), even if viral loads were not detectable at the time of treatment.

We observed an upregulation of cytotoxic and effector memory cell markers in our patient after preoperative treatment with nivolumab/ipilimumab, detected both by IHC analysis (CD3, CD8, CD45RO, and granzyme B) and CyTOF (CD3, CD8, and CD45RO). Similarly, it has been reported that an immunoscore that characterizes cytotoxic and effector memory cells can be correlated with response and outcomes in colorectal cancer (21). Our analysis showed increased PD-L1 expression following neoadjuvant immunotherapy with nivolumab plus ipilimumab. We hypothesize that an increase in CD8⁺ T-cell frequency in the tumor after treatment leads to T-cell activation, PD-1 expression, and IFN γ production within the tumor microenvironment, which in turn may also induce PD-L1 expression (22, 23). A potential additive or synergistic effect of the nivolumab/ipilimumab combination treatment has been described in melanoma (24). These findings support our observation that the patient in our study experienced a complete response.

We demonstrated that the cluster of CD3⁺CD4⁺CD45RO⁺ Foxp3⁺ICOS⁺ cells selectively increased in the tumor microenvironment after preoperative immunotherapy. Interestingly, the presence of CD4⁺Foxp3⁺ Tregs, especially ICOS⁺Foxp3⁺ Tregs, has been generally linked to poor prognosis and decreased survival in HCC as a result of the suppression of antitumor responses (25). However, accumulating data suggest that Foxp3⁺ T cells in human cancer are heterogeneous in phenotype and function (26). In human colorectal cancer and breast cancer, for example, the presence of Foxp3⁺ Tregs has been reported to be predictive of favorable outcome (27, 28). In our case, both Tregs and CD8⁺ effector T cells increased simultaneously. This increase may be an indicator of a CD8⁺ T-cell response, which might overcome the immunosuppressive effects of Tregs. Indeed, the CD8⁺ T-cell/Treg ratio increased slightly in the tumor microenvironment after treatment with nivolumab and ipilimumab, whereas this ratio did not change in adjacent nontumoral liver samples. Previous reports have proposed the relevance of the intratumoral balance of regulatory and cytotoxic T cells in HCC (25). A previous analysis of 302 patients demonstrates that a high intratumoral CD8⁺ effector T-cell/Treg ratio is significantly associated with an improved prognosis following hepatic resection (25). Patients with high CD8⁺ effector T-cell/Treg ratios have significantly longer overall survival (86 months) and disease-free survival (105 months) than those with low CD8⁺ T-cell/Treg ratios (31 and 23 months, respectively; ref. 29).

This study is ongoing, with an expected total enrollment of 45 patients, and we will perform immune monitoring on biological samples from all patients enrolled. The final results may provide more insight into our initial findings reported here and may contribute to a paradigm

shift in perioperative immunotherapy for HCC. This, in turn, may lead to a decreased incidence of HCC recurrence and improved HCC outcomes through the incorporation of immunotherapy in the curative setting.

Acknowledgments

This work was funded by Bristol-Myers Squibb.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87–108. [PubMed: 25651787]
2. Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. *World J Hepatol* 2015;7:245–52. [PubMed: 25729479]
3. Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2015;16:1344–54. [PubMed: 26361969]
4. Zhu AX, Finn RS, Edeline J, Cattani S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol* 2018;19:940–52. [PubMed: 29875066]
5. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (Check-Mate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet North Am Ed* 2017;389:2492–502.
6. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. *J Hepatol* 2017;66:545–51. [PubMed: 27816492]
7. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *J Hepatol* 2013;59:81–8. [PubMed: 23466307]
8. Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. *Cancer Discov* 2016;6:1382–99. [PubMed: 27663893]
9. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med* 2018;24:1649–54. [PubMed: 30297909]
10. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. *N Engl J Med* 2018;378:1976–86. [PubMed: 29658848]
11. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. *J Clin Oncol* 2018;36:3353–60. [PubMed: 30343614]
12. Chalabi M, Fanchi LF, Van den Berg JG, Beets GL, Lopez-Yurda M, Aalbers AG, et al. LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer. *Ann Oncol* 2018;29(suppl_8):mdy424.047.
13. Finck R, Simonds EF, Jager A, Krishnaswamy S, Sachs K, Fantl W, et al. Normalization of mass cytometry data with bead standards. *Cytometry A* 2013;83:483–94. [PubMed: 23512433]
14. Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol* 2013;31:545–52. [PubMed: 23685480]
15. van der Maaten LH. Visualizing data using t-SNE. *J Mach Learn Res* 2008;9: 2579–605.
16. Levine JH, Simonds EF, Bendall SC, Davis KL, Amir el AD, Tadmor MD, et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. *Cell* 2015;162:184–97. [PubMed: 26095251]

17. Li G, Yang Q, Zhu Y, Wang H-R, Chen X, Zhang X, et al. T-Bet and Eomes regulate the balance between the effector/central memory T cells versus memory stem like T cells. *PLoS One* 2013;8:e67401. [PubMed: 23826287]
18. Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, et al. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. *J Immunol* 2010;185:3174–83. [PubMed: 20713880]
19. Wu RC, Hwu P, Radvanyi LG. New insights on the role of CD8(+)CD57(+) T-cells in cancer. *Oncoimmunology* 2012;1:954–6. [PubMed: 23162769]
20. Ramzan M, Sturm N, Decaens T, Bioulac-Sage P, Bancel B, Merle P, et al. Liver-infiltrating CD8+ lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. *Liver Int* 2015;36:434–44. [PubMed: 26215124]
21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 2006;313:1960–4. [PubMed: 17008531]
22. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. *Clin Cancer Res* 2011;17: 4101–9. [PubMed: 21558401]
23. Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFN- γ in cancer progression: a role of PD-L1 induction in the determination of pro- and anti-tumor immunity. *Clin Cancer Res* 2016;22: 2329–34. [PubMed: 27016309]
24. Carlino MS, Long GV. Ipilimumab combined with nivolumab: a standard of care for the treatment of advanced melanoma? *Clin Cancer Res* 2016;22: 3992–8. [PubMed: 27340279]
25. Tu J-F, Ding Y-H, Ying X-H, Wu F-Z, Zhou X-M, Zhang D-K, et al. Regulatory T cells, especially ICOS(+) FOXP3(+) regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. *Sci Rep* 2016;6:35056. [PubMed: 27725696]
26. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Cell Res* 2017;27:109–18. [PubMed: 27995907]
27. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. *Cancer Immunol Immunother* 2011;60:909–18. [PubMed: 21644034]
28. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. *J Clin Oncol* 2009;27:186–92. [PubMed: 19064967]
29. Gao Q, Qiu S-J, Fan J, Zhou J, Wang X-Y, Xiao Y-S, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. *J Clin Oncol* 2007;25: 2586–93. [PubMed: 17577038]




Figure 1.

Pre- and posttreatment CT scans of the responding patient. Arterial phase CT scans taken pretreatment (**A**) and posttreatment (**B**) after one dose of nivolumab plus ipilimumab, followed by one dose of single-agent nivolumab. The tumors initially showed arterial enhancement consistent with HCC but lost this enhancement after treatment.




Figure 2.

Clinical trial schema and IHC analysis showing favorable immune infiltration posttreatment in the responder. **A**, Clinical trial [NCT03222076](#) arm A schema indicating when samples were collected. The dose of nivolumab (indicated in red) was not given due to hepatotoxicity. Time points for blood and tumor tissue collection and the assays performed are indicated by red and blue arrows. q2w, every 2 weeks; q6w, every 6 weeks; q12w, every 12 weeks. **B** and **C**, IHC analysis of pre- and posttreatment hepatic tissues from the HCC patient. **B**, IHC analysis of total T cells (CD3⁺), CD8⁺ T cells, CD45RO-expressing cells, granzyme B (Gr-B)-expressing cells, FoxP3-expressing cells (regulatory T cells), and PD-L1-expressing immune cells (PD-L1 Imm). Mean density + SD is shown for five different regions in the liver at each timepoint. **C**, Representative IHC images of CD3⁺ and CD8⁺ T cells pre- and posttreatment (after resection) from one representative region is shown at a magnification of 20 \times .




Figure 3.

Mass cytometry (CyTOF) analysis of tissues and blood from the responder. Phenograph analysis was performed to determine the frequencies of each cluster in the total CD45⁺ population. **A**, tSNE plot showing the different clusters identified within each cell subpopulation. Clusters 5, 12 (CD8⁺ T-cell effectors), and 8 (regulatory T cell) are shown. NK, natural killer. **B**, Heatmap showing marker expression and frequencies of the different clusters identified. Clusters 5, 12, and 8 are marked by red boxes. **C**, Frequency of activated CD8⁺ T cells (cluster 5) for pre- and posttreatment tumor tissue, pre- and posttreatment nontumoral liver (normal liver), and pre- and posttreatment PBMCs at various time points as indicated. **D**, Frequency of activated CD8⁺ T cells (cluster 12) for pre- and posttreatment tumor tissue, pre- and posttreatment nontumoral liver, and pre- and posttreatment PBMCs at various time points as indicated. **E**, Frequency of CD4⁺ Tregs (cluster 8) for pre- and posttreatment tumor tissue, pre- and posttreatment nontumoral liver, and pre- and posttreatment PBMCs at various time points as indicated. **F**, Effector CD8⁺ T-cell/Treg ratio pre- and posttreatment in tumors and nontumoral liver samples.